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Background and Rationale
Global priorities for research in neglect-
ed infectious diseases (NIDs) can be assess-
ed in different ways, but it is important to
realize that regional priorities may signifi-
cantly differ one from another. The region
of Latin America and the Caribbean (LAC)
is—along with Africa and Asia—more
affected by NIDs than other regions of the
world. Some of the Latin American NIDs
are common to other continents, while
others are very specific or disproportion-
ately affect the Latin American region [1–
3] (Table 1). Because of its huge ecological
diversity, ongoing environmental changes,
and massive migrations, LAC is also a
catalyst for the (re-)emergence and spread-
ing of NIDs, both inside and outside the
subcontinent. Following a colloquium on
NIDs in LAC held in Lima, Peru, between
12 and 14 November 2009, a thematic
workshop was organized with the support
of the European Commission (EC). It
involved 29 scientists (16 from the Amer-
icas, two from the Democratic Republic of
Congo and India, respectively, and nine
from Europe) working on different NIDs
and representing several research areas
from basic to applied. This report summa-
rizes the consensus comments of the expert
group after oral and written consultation. It
is envisaged that this document should
stimulate a debate within the scientific
community and serve as a recommendation
for future actions by international or
regional funding agencies in the area of
NIDs in LAC.
Priority NIDs and Major
Research Gaps in Latin America
and the Caribbean Region
Listing and priority setting for NID
research is a matter of context, and should
not be confused with the burden of the
diseases themselves. The major NIDs in
LAC in terms of disease burden (usually
expressed in terms of disability-adjusted
life years [DALYs] lost) have previously
been listed on the basis of their prevalence
and estimated DALYs [4,5]. However, the
prevalence of many NIDs could be
significantly reduced with existing tools,
making them a focus for improved public
health service delivery rather than a
research priority. The Pan American
Health Organization (PAHO) has thus
set a goal to eliminate or significantly
reduce 12 NIDs in the Americas, before
2015, using existing tools [6]. In the
present policy platform, the scientific
panel focused on priority setting for
regional NIDs from a research perspec-
tive. A rational way to prioritize the
relevance and importance of research for
the large and diverse group of NIDs could
be to use specific indicators of poverty,
mortality, and morbidity, but for several of
these diseases bona fide data are lacking or
unreliable. Furthermore, some groups in
society, typically those in impoverished
living conditions, are usually susceptible to
more than one infection or disease, and
therefore studies or control programs may
need a wider scope [7]. The panel decided
therefore to focus further discussions on
groups of NIDs rather than on specific
diseases (Figure 1). Similarly, the panel
decided not to rank desired drugs, diag-
nostics, and vaccines, as there is an
ongoing effort by (i) the World Health
Organization (WHO) and the Special
Program for Research and Training in
Tropical Diseases (TDR) to identify global
priorities for NIDs and (ii) the Pan
American Health Organization (PAHO)
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to establish a local research agenda for the
Latin American region.
Arthropod vector-borne diseases consti-
tute a first and highly relevant group,
especially because they are strongly pov-
erty related and disease patterns are highly
vulnerable to anthropogenic and environ-
mental changes. In general, there is a lack
of quality and affordable diagnostic tests
available to existing facilities (central
reference laboratories, peripheral labora-
tories, and point-of-care settings). Clinical
evidence is often lacking for the treatments
in use and innovation in drug develop-
ment should be strongly supported. The
role of asymptomatic infections in trans-
mission should be elucidated, while tools
for better epidemiologic surveillance and
well-defined therapeutic strategies for the
chronic carriers are needed. Epidemiolog-
ic studies, mainly on the competence and
transmission capacity of (secondary) vec-
tors, are needed, especially where envi-
ronmental changes and disturbance of life
cycles occur. Innovation in vector control
tools and research on insecticide resistance
is crucial in all vector control programs,
while studies on social determinants are of
special importance in relation to accep-
tance by local communities of delivery of
control measures.
Soil- and tissue-transmitted helminths
represent a second major group of pover-
ty-related diseases; these infections are
impediments to the physical and mental
growth of children and a source of
increasing social distress in LAC. Various
studies in LAC have shown that soil-
transmitted helminths (STHs) can be
eliminated or reduced in cost-effective
ways using existing tools [8]. However,
the impact of control programs needs to be
analyzed and studies on potential drug
resistance need to be carried out in areas
where only limited success was achieved.
Identification and optimization of best
practices should be supported, and linked
to regional networking for research trans-
fer and uptake into health policies and
practice aimed at all levels of society, with
Table 1. Examples of Some Major NIDs Affecting Latin America and the Caribbean.
NIDs Affecting the Latin
American, Caribbean,
and Other Regions
NIDs with a Disproportionate
Impact in the Latin American
Caribbean Region
PAHO-targeted NIDs Congenital syphilis
Leprosy
Lymphatic filariasis
Neonatal tetanus
Onchocerciasis
Plague
Rabies
Schistosomiasis
Trachoma
Chagas disease
Soil-transmitted helminthiasis
Other NIDs Buruli ulcer
Dengue
Visceral leishmaniasis
Bartonellosis
Echinococcosis
Hantavirus
Histoplasmosis
Leptospirosis
Muco-cutaneous leishmaniasis
(Espundia)
Paracoccidioidomycosis
doi:10.1371/journal.pntd.0000780.t001
Figure 1. Five groups of diseases were identified as priorities for research in LAC, and examples of key diseases belonging to each
group are indicated. Note: there is an overlap between the emerging viral diseases of regional importance and the arthropod vector-borne
diseases.
doi:10.1371/journal.pntd.0000780.g001
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an expected positive impact on health.
Evaluation of the impact of chronic
helminth infection on immunity against
other concomitant infections and on
vaccination efficacy is recognized as a
critical research gap.
Third, endemic mycosis is caused by a
number of pathogens, some of which are
specific to the Latin American and
Caribbean region. The well-established
therapeutic and prophylactic regimens for
bacterial infections enable longer survival
of immunosupressed patients (ISPs) but
have contributed to increased rates of
fungal infections. Epidemiology of fungal
infections in ISPs includes an increase in
non-albicans Candida spp. and an increase
in aspergillosis with its high mortality,
which can reach up to 80% in some cases,
despite treatments [9]. Therapeutic limi-
tations associated with critically ill pa-
tients demand a deeper understanding of
the interactions between fungal cells and
the immune system of the host. Neutro-
penic, oncological ISPs under aggressive
anti-tumoral chemotherapy and intensive
care patients are highly susceptible to
invasive fungal infections. A subset of
such patients can develop infections more
frequently, which may indicate that
different host genotypes contribute to an
increased resistance/susceptibility to fun-
gal infections [10–12]. The main areas of
research and development that need to be
targeted are diagnosis and identification
with new tools, epidemiologic determi-
nants of infection, new therapeutic drugs,
and interaction with other pathologies
[13].
Fourth, emerging, non-arthropod-borne
viral diseases of regional importance are
poorly studied in terms of epidemiology and
differential diagnosis. LAC as a region has a
significant disease burden due to new and
re-emerging viral diseases, especially zoo-
notic diseases, and their occurrence and
burden of disease remain largely underesti-
mated. For instance, the newly emerging
HTLV-1 is rarely detected in Latin Amer-
ican and Caribbean countries, with the
exception of Peru, although it has been
shown to be the cause of significant
morbidity in other areas of the world. A
comparative study in LAC that includes
several countries and regions would shed
light on this issue.
The fifth and final priority identified
was sexually transmitted diseases (STDs)
other than HIV/AIDS. STDs constitute a
complex of infections of different origins
and pathogens that need regular updating
on species and strain identification associ-
ated with early diagnosis, treatment, and
drug resistance.
Technological Strengths and
Opportunities in Latin America
and the Caribbean Region
A second approach taken for priority
setting was to identify research and techno-
logical strengths and opportunities in LAC.
Several research and technological networks
already exist in the region, and these might
constitute promising platforms for new cost-
effective research actions (Table S1). This
‘‘top-down’’ approach also aimed to list
domains in which capacity strengthening
should be further undertaken.
Significant disparities exist in research
and technological facilities among Latin
American and Caribbean countries, with
major research investments in countries like
Brazil and Cuba, and major difficulties with
brain drain in many countries, including
those in Central America. Major disparities
also exist within many countries, with some
countries recognized internationally for the
caliber of their research. Well-established
regional institutions could therefore play a
major role as focal points for South–South
collaborations and capacity strengthening.
The possibility of networking the major
research institutes in LAC, much like
Institut Pasteur has done in the past, should
be entertained. PAHOhas definitely offered
opportunities for this in the past, as did
WHO/TDR, and major donors such as the
European Union should be encouraged to
support such initiatives. At the same time,
North–South partnerships should avoid the
temptation to focus only on strong partner
countries from the South, but should also
consider weaker ones, where capacity
strengthening would bring an added value.
Among the specific research and techno-
logical strengths/opportunities identified by
the panel in the region, the following
deserve particular attention.
Natural Products Research
The biodiversity found in LAC is one of
the richest in the world, yet its potential as
a source of new pharmaceuticals or
agrochemicals has not been fully realized.
The Latin America Network for Research
on Bioactive Natural Compounds (LAN-
BIO) was created to promote research on
natural products in the region. These
studies represent an important avenue to
promote local research capacity and to
generate new knowledge, as well as to
attract resources for sustainable research
activities. No single country has all the
natural resources, manpower, and facilities
required. Complementarity in regional
natural products research activities is
therefore one critical reason for the
existence of LANBIO. However, there is
a need to strengthen its capacity to allow
for the research, production, and testing of
candidate products to meet current inter-
national quality standards.
Clinical/Epidemiologic Research
In spite of great limitations and dispar-
ities among countries, several excellent
research centers have developed in the
region. They have been pivotal in generat-
ing knowledge of endemic pathologies,
providing highly specialized professional
training, promoting multicentric and mul-
tinational basic as well as clinical and
epidemiologic research, and incorporating
new technologies and/or procedures.
Therefore, numerous opportunities exist
to expand and reinforce such achievements
through strategic partnerships and associa-
tions with similar institutions in both
developing and developed countries. Over
the last few years, WHO and TDR have
supported the training of scientists from
disease-endemic countries, including Latin
American and Caribbean countries, in
both good laboratory practices (GLPs)
and good clinical practices (GCPs). This
has led to the establishment of a network of
GLP trainers who can provide expert
assistance in future research activities.
WHO/TDR has also promoted the estab-
lishment of GLP-compliant laboratories
that will enable the production of high-
quality data for both non-clinical safety
studies as well as for clinical and epidemi-
ologic studies [14]. New research efforts
can benefit from these advancements,
which, in turn, will consolidate and
strengthen further training initiatives in
good practices related to social sciences,
bioethics, project planning, and evaluation.
Medical Entomology
LAC has prioritized the development of
human resources on medical entomology
(ME) in the past, but unfortunately this
situation is changing. The biology and
behavior of vector species, and even
knowledge about which vectors are impli-
cated in specific diseases, still remain
undefined in many cases in LAC. Decisions
about vector control are often based on
extrapolations from other regions (Africa or
Asia). Research on new and improved
surveillance and control tools/strategies
should be encouraged. LAC has acquired
expertise in the control of specific NIDs,
most notably Chagas disease. Elimination
and control in several countries has been
achieved through well-organized programs
and regional discussions that have included
a large number of stakeholders. Multidisci-
plinary research played a major role in
paving the way for program launch, but
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also to monitor it over the time. The
expertise accrued in terms of data ex-
change, standardization of technologies,
training at different levels, usage of infra-
structures, and transfer of sustainable
technology can be applied to other diseases
or to groups of diseases sharing similar
aspects in their life cycle or clinical profile.
Social and public health studies should be
integrated, and here again the experience
acquired with Chagas disease could easily
be applied to other ‘‘social diseases’’ [15].
Even ‘‘successful’’ control strategies such as
the Chagas disease control program could
be further strengthened, as many challeng-
es lie ahead for the control of vector
transmission (for example, the presence of
relevant sylvatic populations [16] or resis-
tance to residual insecticides [17]). Similar-
ly, non-chemical control, in general, needs
further studying if we take into account the
unsustainable and limited efficacy as well as
the potential impact of pyrethroid-based
pesticides on human health [18]. ME
research in LAC needs capacity strength-
ening, in both managerial as well as
technical issues, i.e., the use of geographic
information system (GIS) and remote
sensing technologies to study vector distri-
bution [19], and molecular tools that help
in the determination of vector species and
vector incrimination, amongst others, with-
out neglecting the basic skills of vector
behavior studies. Integrated vector man-
agement (IVM) and translational research
for vector control (i.e., how to translate
research outputs into policy) should be
encouraged, considering the similar chal-
lenges encountered among different arthro-
pod-borne diseases. Collaboration between
existing networks (Table S1) will encourage
new partnered research and integrated
strategies in vector control.
Genomics and Bioinformatics
Early efforts in this research area have
definitely helped countries in LAC to
increase their scientific impact at the
international level and to stop their brain
drain [17], leading to a series of well-
established networks (Table S1). The on-
going technological revolution in new high-
throughput sequencing technologies repre-
sents a unique opportunity for LAC. On
the one hand, this revolution will democ-
ratize a technology that, until now, has
largely been reserved for large genome
centers [20]. On the other hand, the new
technologies offer the possibility to under-
take parallel genome-wide sequencing of
different strains representative of the clin-
ical and phenotypic diversity of a given
microorganism [21,22]. This approach is
likely to provide an unlimited source of
information for epidemiology, diagnostics,
tracking of drug resistance, drug and
vaccine discovery, and pharmacogenomics,
among others. Recognizing the huge bio-
diversity that exists in LAC, the strength-
ening of a new generation of genomic tools
could provide considerable added value to
the regional research environment.
Biotechnology Incubators
A particular case of South–South part-
nership concerns small and medium
enterprises (SMEs) in the biotechnology
sector in LAC. The region has a small but
growing number of countries with estab-
lished biotechnology SMEs that would be
in a position to contribute to the produc-
tion of new drugs, diagnostic kits, and
vaccines for NIDs. South–South collabo-
ration would contribute to connect pro-
viders and users, including more devel-
oped and less developed research groups,
countries, or disease foci. The inclusion of
local SMEs in academic research collab-
orations could result in important cross-
fertilization between the two sectors, and
such public–private partnerships should be
strongly encouraged by both private and
public research funders. Although the
latter is still new in most of LAC, there
are leading institutions experienced in the
transfer of technological development into
products. Most of the products are geared
to supply the needs of the Ministries of
Health and research is still incipient in
these facilities. Although a significant
increase in biotech parks throughout
LAC has occurred, there is still a large
gap between the transfer of ‘‘prototypes’’
to production. Significant experience has
been gained from Brazilian institutions
such as FIOCRUZ and Instituto Butantan
on product development and production.
These institutes have been able to supply
the country and export several of the basic
vaccines and pharmaceuticals needed for
the nation’s health programs. However,
there is still a need for an increase in
interaction and transfer of technological
development in health among the biotechs
in Latin American and Caribbean coun-
tries and the available industrial parks in
those countries. This process is crucial to
position LAC at a significantly higher level
of competitiveness in supplying the coun-
tries with pharmaceuticals and biologicals
in all health fields, including NIDs.
Cross-Cutting Issues and
Collaborative Research
Research activities can be driven by
different factors, and supported in varying
degrees by governments, funding agencies,
economic interests, patients’ organizations,
and research communities themselves.
The desire to overcome a major public
health problem may lead to needs-driven
research. Opportunity-driven research can
come from an interest in potential eco-
nomic gain, or the examination of readily
available data from routinely collected
administrative databases or from a partic-
ular technological or scientific situation.
Hypothesis-driven research is normally
initiated by researchers themselves from
scientific curiosity or in a search for basic
biological mechanisms. The present panel
of experts suggested that the ideal research
consortium on NIDs in LAC should be a
blend of needs-, hypothesis-, and oppor-
tunity-driven research. This strongly de-
pends on a number of factors ranging from
infrastructures to sustainability and trained
local personnel so that scientific autonomy
and excellence become the rule in LAC, as
many countries have already shown [13].
The need for better interaction between
different scientific areas, which range from
social aspects to vector biology and control,
immunogenetics, genomics, biotechnology,
community participation, and dissemination
of information, was strongly recommended.
This has also previously been highlighted in
the frame of the LAC–European Union
Cooperation (ALCUE) Health workshop
[23]. Major developments in biotechnology
have not necessarily been applied to im-
prove health conditions, due to many
different reasons, including a lack of com-
munication between the research environ-
ment and policy-makers or the lack of a
proper needs-based agenda; at the same
time, major social changes associated with
overpopulated urbanized areas, major mi-
grations, and other upheavals have consid-
erably diminished the proper use or appli-
cation of control programs. When possible
and relevant, research efforts should be
coordinated to enhance targeted, cost-effec-
tive objectives. In this context, strengthening
research on prediction, identification, mod-
eling, and surveillance of NIDs is an
example of a cross-cutting priority. The
aim would be to develop a network of
scientists and a battery of tools allowing (i) a
better surveillance of the (re-)emergence and
spreading of LAC NIDs and their associated
risks, and (ii) integrated disease manage-
ment. An interdisciplinary approach should
be followed. Research in public health,
health systems, and epidemics preparedness
should constitute one of the core elements,
among others, of the identification of better
parameters to quantify the burden of
disease. A clinical component would also
be needed and should aim, among others, at
standardized case definitions: from asymp-
www.plosntds.org 4 October 2010 | Volume 4 | Issue 10 | e780
tomatic to the different clinical manifesta-
tions of the respective diseases. The labora-
tory component should standardize the
existing tools for the detection and typing
of pathogens and apply them in a few model
situations; specific attention should be paid
to the performances of the assays in
asymptomatic individuals. Genomic and
post-genomic approaches might be consid-
ered for a high-throughput characterization
of pathogen diversity. Another laboratory
component should focus on the vectors (if
any) with a special emphasis on their
ecology; the search for potential secondary
vectors and their capacity for transmission
should be encouraged. Environmental sci-
ences and mathematical modeling should
interact closely with the previous domains in
order to provide an integrated package of
validated surveillance tools that would be
useful to health authorities. The research
consortia should involve members of differ-
ent existing regional networks and pay
particular attention to promote dissemina-
tion of information (at all levels).
Conclusion
Research priorities for NIDs are strong-
ly influenced by social and regional
contexts. While global priorities for NID
research are recognized, it is important to
realize that regional priorities may be
significantly different. We have identified
the following key areas for research in
NIDs for LAC: arthropod vector-borne
diseases, soil- and tissue-transmitted hel-
minths, endemic mycosis, emerging non-
arthropod-borne viral diseases, and STDs
other than HIV/AIDS. Research should
build on existing strengths (such as net-
works that are already functional), but also
promote further North–South as well as
South–South partnerships. Particular op-
portunities are identified for research in
natural products, clinical and epidemio-
logic research, ME, genomics/bioinfor-
matics, and applied biotechnology. Clini-
cal research should be linked with public
health as well as basic research. ME
should be encouraged through a combi-
nation of field studies and basic research,
including molecular studies in the vectors
and in the response to insecticides. Geno-
mics with special emphasis in bioinfor-
matics and deep sequencing could provide
innovative information on the diversity of
pathogens present in the region. The
involvement of Southern SMEs would be
an opportunity to provide local solutions
to neglected problems.
Policy-makers, private charities/foun-
dations, and national and international
funding agencies are increasingly support-
ing research in NIDs. National Councils
for Science and Technology exist in
practically all Latin American and Carib-
bean, countries and most provide some
funding opportunities for NID research,
but at very different levels of magnitude.
Many research teams in LAC are there-
fore dependent on collaborations with
international research teams and funders.
This can play an important role in priority
setting by allocating attention, funding,
and other resources to some activities, but
not to others. Continued dialogue between
research funders and policy-makers on the
one hand, and the LAC research commu-
nity on the other, is therefore pivotal in
establishing an intelligent research agenda.
Supporting Information
Table S1 Examples of networks and
initiatives for regional scientific collabora-
tion in LAC with relevance to NIDs
Found at: doi:10.1371/journal.pntd.
0000780.s001 (0.05 MB DOC)
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